Dehospitalization: pharmacoeconomic aspects and the impacts of days saved from hospitalization in renal transplant patients using carbapenems
DOI:
https://doi.org/10.30968/rbfhss.2023.143.0994Abstract
Purpose: To carry out an analysis cost minimization and patient outcomes submitted to OPAT of carbapenems in a teaching hospital in the state of Ceará. Methodology: This is a descriptive and retrospective observational study with a quantitative, characterized as a pharmacoeconomic analysis of cost minimization of the treatment performed with meropenem in patients hospitalized in the renal transplant units of a teaching hospital in the state of Ceará and outpatients who migrated for OPAT with ertapenem in outpatient services. The clinical outcome was evaluated by measuring the readmission rate up to 30 days after the end of treatment. Results: Eight patients were selected for the study. The microbiological profile verified the predominance of infections caused by Enterobacteriaceae (Klebsiella pneumoniae and Escherichia coli), representing 75% of the microbiological isolates. The cost analysis found a daily cost of U$ 60.04 in the treatment conducted with meropenem in hospitalized patients, in contrast, the daily cost in OPAT performed with ertapenem was US$ 78.79. The treatments performed totaled a cost of U$ 7,515.89 for the institution, and in an unprecedented way we evidenced a cost reduced from US$ 1029.45 if the treatment were fully carried out during the hospitalization (US$ 6,484.44). Conclusion: There was an incremental cost during dehospitalization in relation to the treatment performed during hospitalization hospital, on the other hand, a higher bed turnover can be observed, which makes it possible to perform more transplants.
Downloads
References
Mahoney MV, Childs-Kean LM, Khan P, et al. Recent Updates in Antimicrobial Stewardship in Outpatient Parenteral Antimicrobial Therapy. Curr Infect Dis Rep. 2021;23(12):24. DOI: 10.1007/s11908-021-00766-x.
Hamad Y, Lane MA, Beekmann SE, Polgreen PM, Keller SC. Perspectives of United States-based Infectious Diseases Physicians on Outpatient Parenteral Antimicrobial Therapy Practice. Open Forum Infect Dis. 2019;6(10):ofz363. DOI: 10.1093/ofid/ofz363.
Durojaiye OC, Cartwright K, Ntziora F. Outpatient parenteral antimicrobial therapy (OPAT) in the UK: a cross-sectional survey of acute hospital trusts and health boards. Diagn Microbiol Infect Dis. 2019;93(1):58-62. DOI: 10.1016/j.diagmicrobio.2018.07.013.
Sociedade Brasileira de Infectologia. Diretrizes Brasileiras para Terapia Antimicrobiana parenteral ambulatorial. 2020. 5. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007; 67(7):1027-52. DOI: 10.2165/00003495-200767070-00006.
Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extendedspectrum-β-lactamase-producing Gram-negative organisms. Antimicrob Chemother. 2010; 65(7):1510-3. DOI: 10.1093/jac/dkq152.
Tice AD. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother. 2004;53 (2):83-86. DOI: 10.1093/jac/dkh210.
Ramasubramanian V, Murlidharan P, Nambi S, et al. Efficacy and Cost Comparison of Ertapenem as Outpatient Parenteral Antimicrobial Therapy in Acute Pyelonephritis due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae. Indian J Nephrol. 2018;28(5): 351–357. DOI: 10.4103/ijn.IJN_207_17.
Dimitrova M, Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open. 2021;11(9):e049733. DOI: 10.1136/bmjopen-2021-049733.
Taminato M, Fram D, Pereira RRF, et al. Infection related to Klebsiella pneumoniae producing carbapenemase in renal transplant patients. Rev Bras 341 Enferm. 2019; 72(3):760-6. DOI: http://dx.doi.org/10.1590/0034-7167-2019-0009.
Brakemeier S, Taxeidi SI, Zukunft B, et l. Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae –Related Urinary Tract Infection in Kidney Transplant Recipients: risk factors, treatment, and long-term outcome. Transplant 346 Proc. 2017;49(8):1757-1765. DOI: http://dx.doi.org/10.1016/j.transproceed.2017.06.033.
Espinar MJ, Miranda IM, Costa-de-Oliveira S, et al. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumonia Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology. PLoS ONE. 10(8): e0134737. DOI:10.1371/journal.pone.0134737.
Zhang Y, Wang Y, Van Driel ML, et al. Network meta-analysis andpharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control. 2019; (8), 72. DOI: https://doi.org/10.1186/s13756-019-0518-2.
Peña A, Zambrano A, Alvarado M, et al. Evaluación de la efectividad, seguridad y costos del tratamiento antimicrobiano intravenoso ambulatorio (TAIA) vs hospitalizado en infección urinaria en pediatria. Rev Chil Infectol. 2013;30 (4): 426-434.
Izaias EM, Dellaroza MSG, Rossaneis MA, Belei RA. Custo e caracterização de infecção hospitalar em idosos. Ciênc Saúde Colet. 2014;9(8):3395-3402. DOI: org/10.1590/1413-81232014198.12732013.
Psaltikidis EM, Silva END, Moretti ML, et al. Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):341-352. DOI: 10.1080/14737167.2019.1541404.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
